Although targeted therapies for a few types of RAS/RAF mutant colorectal cancers (such as those with KRASG12C and BRAFV600E mutations) have been clinically applied in recent years [1], these mutations are relatively rare, and no effective treatment has been developed for most patients with other RAS/BRAF mutations. This evidence concerns the gene BRAF and colorectal cancer.